Company
Elixirgen Therapeutics, Inc.
We develop life-changing therapies, focusing on rare diseases and aging-associated diseases using our cutting-edge technologies.
Also known as Elixirgen Therapeutics
- Business model
- B2B
- Legal name
- Elixirgen Therapeutics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Development of treatments for rare diseases through cell therapy using ZSCAN4
Funding snapshot
- Total raised
- $34.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $4M2025-10-30
Funding rounds
- Round, 2025
- $4M2025-10-30, SEC form D sold, 1 investor
- Round, 2025
- $3.6M2025-03-31, SEC form D sold, 2 investors
- Round, 2025
- $600K2025-01-30, SEC form D sold, 2 investors
- Round, 2023
- $7M2023-11-09, SEC form D sold, 1 investor
- Round, 2022
- $5M2022-09-14, SEC form D sold, 1 investor
- Round, 2021
- $4.2M2021-02-02, SEC form D sold, 2 investors
- Round, 2019
- $5.7M2019-11-19, SEC form D sold, 3 investors
- Round, 2018
- $4M2018-06-13, SEC form D sold, 1 investor
Products
- Web
- Bobcat mRNA
- Web
- EXG-34217
- Web
- EXG-7001
- Web
- ZSCAN4
Loading relationship preview